NCT00422591View on ClinicalTrials.gov

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
LeukemiaAcute Myeloid LeukemiaAML
Interventions
DRUG

Cytarabine

1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).

DRUG

Idarubicin

12 mg/m2 IV over 1 hour daily x 3 (days 1-3)

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00422591 - Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter